Suppr超能文献

蛋白酶体调节颗粒的小分子抑制剂。

Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

机构信息

Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, Indiana, 47907, USA.

出版信息

Chembiochem. 2019 Jul 15;20(14):1739-1753. doi: 10.1002/cbic.201900017. Epub 2019 May 24.

Abstract

Cells need to synthesize and degrade proteins consistently. Maintaining a balanced level of protein in the cell requires a carefully controlled system and significant energy. Degradation of unwanted or damaged proteins into smaller peptide units can be accomplished by the proteasome. The proteasome is composed of two main subunits. The first is the core particle (20S CP), and within this core particle are three types of threonine proteases. The second is the regulatory complex (19S RP), which has a myriad of activities including recognizing proteins marked for degradation and shuttling the protein into the 20S CP to be degraded. Small-molecule inhibitors of the 20S CP have been developed and are exceptional treatments for multiple myeloma (MM). 20S CP inhibitors disrupt the protein balance, leading to cellular stress and eventually to cell death. Unfortunately, the 20S CP inhibitors currently available have dose-limiting off-target effects and resistance can be acquired rapidly. Herein, we discuss small molecules that have been discovered to interact with the 19S RP subunit or with a protein closely associated with 19S RP activity. These molecules still elicit their toxicity by preventing the proteasome from degrading proteins, but do so through different mechanisms of action.

摘要

细胞需要持续合成和降解蛋白质。为了在细胞内维持蛋白质的平衡水平,需要一个精心控制的系统和大量的能量。蛋白酶体可以将不需要的或受损的蛋白质降解成较小的肽单位。蛋白酶体由两个主要亚基组成。第一个是核心颗粒(20S CP),在这个核心颗粒内有三种类型的苏氨酸蛋白酶。第二个是调节复合物(19S RP),它具有多种活性,包括识别标记为降解的蛋白质并将其运送到 20S CP 中进行降解。已经开发出 20S CP 的小分子抑制剂,是治疗多发性骨髓瘤(MM)的特效药物。20S CP 抑制剂会破坏蛋白质平衡,导致细胞应激,最终导致细胞死亡。不幸的是,目前可用的 20S CP 抑制剂具有剂量限制的脱靶效应,并且可以迅速产生耐药性。本文讨论了一些小分子,它们被发现与 19S RP 亚基或与 19S RP 活性密切相关的蛋白质相互作用。这些分子通过阻止蛋白酶体降解蛋白质来发挥其毒性作用,但它们通过不同的作用机制来实现这一点。

相似文献

1
Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.蛋白酶体调节颗粒的小分子抑制剂。
Chembiochem. 2019 Jul 15;20(14):1739-1753. doi: 10.1002/cbic.201900017. Epub 2019 May 24.
6
Assembly of the 20S proteasome.20S蛋白酶体的组装
Biochim Biophys Acta. 2014 Jan;1843(1):2-12. doi: 10.1016/j.bbamcr.2013.03.008. Epub 2013 Mar 16.
7
Proteasome-associated deubiquitinases and cancer.蛋白酶体相关去泛素化酶与癌症
Cancer Metastasis Rev. 2017 Dec;36(4):635-653. doi: 10.1007/s10555-017-9697-6.
8
Proteasome deubiquitinases as novel targets for cancer therapy.蛋白酶体去泛素化酶作为癌症治疗的新靶点。
Int J Biochem Cell Biol. 2012 Nov;44(11):1729-38. doi: 10.1016/j.biocel.2012.07.011. Epub 2012 Jul 20.
9
Structure-Driven Developments of 26S Proteasome Inhibitors.结构导向的 26S 蛋白酶体抑制剂的开发。
Annu Rev Pharmacol Toxicol. 2016;56:191-209. doi: 10.1146/annurev-pharmtox-010814-124727.

引用本文的文献

本文引用的文献

5
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer.用于治疗卵巢癌的共价Rpn13结合抑制剂
ACS Omega. 2018 Sep 30;3(9):11917-11929. doi: 10.1021/acsomega.8b01479. Epub 2018 Sep 27.
7
Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.Gankyrin 通过促进肿瘤抑制蛋白降解来驱动肝细胞增殖。
Cell Mol Gastroenterol Hepatol. 2018 May 24;6(3):239-255. doi: 10.1016/j.jcmgh.2018.05.007. eCollection 2018.
10
Transcriptome-wide discovery of coding and noncoding RNA-binding proteins.转录组范围内编码和非编码 RNA 结合蛋白的发现。
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E3879-E3887. doi: 10.1073/pnas.1718406115. Epub 2018 Apr 10.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验